pain treatment News
-
DYV-700 Gout Abstract
Pilot, Randomized, Double-Blinded, Placebo Controlled Efficacy and Safety Study of a Transdermal Alkalinizing and Pain Relieving Treatment for Acute Gout Pain Objectives: Gout is characterized by a build-up of monosodium urate (MSU) crystals in and around the joints. MSU crystal formation and dissolution is affected by pH. There are reports in the literature of the use of alkalization agents, ...
-
Meagan Medical Inc. Announces Issuance of a Key U.S. Patent for a Disruptive Chronic Pain Treatment using Spinal Cord Stimulation
Patent provides protection for High Frequency Spinal Cord Stimulation with Beat Technology Vancouver, Washington – March 20, 2015 – Meagan Medical Inc., a clinical research and medical device development company focused on investigating and developing optimal ways of managing and controlling pain, announced today the issuance of a key patent related to a unique ...
-
Profound Medical to Participate in A.G.P.’s Virtual MedTech Summer Conference
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management will participate in A.G.P.’s Virtual MedTech Summer Conference on Thursday, July 29, 2021. The event will consist of ...
-
NBC News’ TODAY Features the Minimally Invasive Intracept® Procedure for Chronic Vertebrogenic Low Back Pain
Relievant Medsystems shared today that the company’s breakthrough chronic low back pain treatment, the Intracept Procedure, was featured on NBC’s TODAY this morning. The full segment can be viewed here. “This is an exciting story, not only for the patients I’ve treated, but also for the millions of patients with chronic vertebrogenic low back pain who will now learn about ...
-
Profound Medical Present at the Canaccord Genuity 40th Annual Growth Conference
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, announced today that management will present ...
-
Profound Medical to Participate in the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management will participate in a fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on Thursday, February 18, ...
-
Nevro to Present at Citi`s 2022 Virtual Healthcare Conference
REDWOOD CITY, Calif., Jan. 31, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, will present at Citi's 2022 Virtual Healthcare Conference on Thursday, February 24, 2022 at 12:30 pm Eastern ...
By Nevro Corp.
-
Profound Medical to Present at the Cantor Virtual Global Healthcare Conference
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, announced today that management will present ...
-
Profound Medical to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Virtual Conference
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, to be held virtually ...
-
Profound Medical to Participate in March Investor Conferences
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will participate in two investor conferences in March. 42nd Annual Cowen Health Care Conference: Profound is scheduled ...
-
Publication of Two-Year EVOKE Double-Blind Randomized Controlled Trial Results in JAMA Neurology Demonstrate Sustained Superiority of Evoke® Closed-Loop over Open-Loop Spinal Cord Stimulation
Saluda Medical Pty Limited (“Saluda Medical”), a global company on a mission to revolutionize the field of neuromodulation with an emerging portfolio of therapies driven by advanced closed-loop technologies designed to treat debilitating neurological disorders, today announced long-term results of its double-blind Level 1 EVOKE randomized controlled trial (RCT) published online in ...
-
Nevro to Report Fourth Quarter and Full-Year 2021 Financial Results
Company to Host Conference Call on Wednesday, February 23, 2022 at 1:30 pm PT / 4:30 pm ET. REDWOOD CITY, Calif., Jan. 24, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the company will report its financial results for the fourth quarter and full-year ...
By Nevro Corp.
-
Nevro Named to 2022 Bloomberg Gender-Equality Index
Leading Indicator Aimed at Increasing Transparency Surrounding Gender-Related Practices and Policies. REDWOOD CITY, Calif., Jan. 26, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has been named to the 2022 Bloomberg Gender-Equality Index (GEI). The ...
By Nevro Corp.
-
Nevro Announces UnitedHealthcare Coverage for High-Frequency 10 kHz Therapy for the Treatment of Painful Diabetic Neuropathy
REDWOOD CITY, Calif., Jan. 4, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that UnitedHealthcare, the largest private health insurance company in the United States, will provide coverage for the company's high-frequency 10 kHz Therapy for the treatment of ...
By Nevro Corp.
-
R&D 100 Award for IT/Electrical Technology is Fourth Prestigious Win for Nalu Medical
Nalu Medical, Inc. (“Nalu”) is named the R&D 100 Award winner for IT/Electrical technology. For nearly 60 years, the coveted R&D 100 Awards have recognized new products for their technological significance in industry sectors spanning telecommunications, high-energy physics, software, manufacturing, and biotechnology. This is the fourth major award1,2,3 recognizing Nalu for ...
-
Profound Medical’s TULSA-PRO® Now Compatible with GE Healthcare’s 3T MRI Scanners
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today confirmed the TULSA-PRO® system’s new compatibility with GE Healthcare’s 3T Magnetic Resonance Imaging (“MRI”) scanners. ...
-
Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2021 Revenue
Fourth Quarter 2021 Worldwide Revenue of Approximately $102.5 Million. Full-Year 2021 Worldwide Revenue of Approximately $386.6 Million Company Expects to Exceed High End of Previously Provided Fourth Quarter 2021 Non-GAAP Adjusted EBITDA Guidance Company to Present Today at J.P. Morgan Healthcare Conference at 4:30 pm Eastern Time. REDWOOD CITY, Calif., Jan. 10, 2022 /PRNewswire/ -- Nevro Corp. ...
By Nevro Corp.
-
Shonan Kamakura Advanced Medical Center Begins Treatment with Hitachi`s First Dedicated Compact Proton Therapy System
Hitachi, Ltd. (TSE: 6501, ”Hitachi”) today announced that “Shonan Kamakura Advanced Medical Center” at Shonan Kamakura General Hospital of Tokushukai Medical Group, where Hitachi's compact proton therapy system (hereafter, “the system”) has been installed, has commenced treatment with the system on 31 January 2022. This is the first order for Hitachi’s ...
-
Profound Medical Receives FDA HDE Approval for Sonalleve
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) announced today that Sonalleve® has received U.S. Food and Drug Administration (“FDA”) approval under a Humanitarian Device Exemption (“HDE”) for the treatment of osteoid osteoma. Osteoid osteoma is a non-cancerous bone tumor that occurs most often in the long bones of ...
-
Gelmetix closes successful £5 million capital raise, progresses to first-in-human trial
Medtech start-up Gelmetix, the developer of a first-in-class polymer treatment for chronic lower back pain, has closed a successful £5 million Series C equity financing round. Following successful in-vivo and pre-clinical studies, the University of Manchester spin-out will now use the additional capital to fund its upcoming first-in-human (FIH) trial and preparing for the pivotal study. ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you